Potentially hallucinogenic 5-hydroxytryptamine receptor ligands bufotenine and dimethyltryptamine in blood and tissues.
Jorma Kärkkäinen, T Forsström, J Tornaeus, K Wähälä, P Kiuru, A Honkanen, U H Stenman, U Turpeinen, A Hesso
Scandinavian Journal of Clinical and Laboratory Investigation 2005 DOI: 10.1080/00365510510013604 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Empirical study Peer reviewed |
|---|---|
| Population | Human tissues, including urine, blood, and stools, as well as animal tissues |
| Topics | DMT 5-MeO-DMT |
| Keywords | Internal psychedelics Human body Internal chemistry Physiological chemistry Biological compounds Blood Stools Intestinal function Chemical quantification Advanced detection methods Metabolomics; keywords: quantify Undetected Discovery Advanced mass spectrometry Digestive system Gut physiology Bufotenine |
| Citations | 50 |
| Key points | Large amounts of bufotenine were detected in human stools, indicating a potential role in intestinal function. |
Abstract
Bufotenine and N,N-dimethyltryptamine (DMT) are hallucinogenic dimethylated indolethylamines (DMIAs) formed from serotonin and tryptamine by the enzyme indolethylamine N-methyltransferase (INMT) ubiquitously present in non-neural tissues. In mammals, endogenous bufotenine and DMT have been identified only in human urine. The DMIAs bind effectively to 5HT receptors and their administration causes a variety of autonomic effects, which may reflect their actual physiological function. Endogenous levels of bufotenine and DMT in blood and a number of animal and human tissues were determined using highly sensitive and specific quantitative mass spectrometric techniques. A new finding was the detection of large amounts of bufotenine in stools, which may be an indication of its role in intestinal function. It is suggested that fecal and urinary bufotenine originate from epithelial cells of the intestine and the kidney, respectively, although the possibility of their synthesis by intestinal bacteria cannot be excluded. Only small amounts of the DMIAs were found in somatic or neural tissues and none in blood. This can be explained by rapid catabolism of the DMIAs by mitochondrial monoamino-oxidase or by the fact that the dimethylated products of serotonin and tryptamine are not formed in significant amounts in most mammalian tissues despite the widespread presence of INMT in tissues.
Citations in the library
Cited by 29
- Neuropharmacology of N,N-dimethyltryptamine Brain Research Bulletin April 30, 2016
- Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells. PLoS One 2014
- N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function Frontiers in Neuroscience August 6, 2018
- A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955-2010. Drug Testing and Analysis 2012
- Dark Classics in Chemical Neuroscience:N,N-Dimethyltryptamine (DMT) ACS Chemical Neuroscience July 23, 2018
and 24 more in the library
Cites 4
- Dimethyltryptamine levels in blood of schizophrenic patients and control subjects Psychopharmacology 1976
- Tissue distribution, metabolism and effects of bufotenine administered to rats. Neuropharmacology July 1, 1995
- Distribution of the hallucinogens N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine in rat brain following intraperitoneal injection: application of a new solid-phase extraction LC-APcI-MS-MS-isotope dilution method. Journal of Chromatography. B, Biomedical Sciences and Applications February 10, 2001
- Urinary excretion of bufotenin (N,N-dimethyl-5-hydroxytryptamine) is increased in suspicious violent offenders: a confirmatory study. Psychiatry Research September 29, 1995